Table. Baseline Characteristics According to Treatment Assignment in Very High-Risk (VHR) and Non-VHR Patients With Atherosclerotic Cardiovascular Disease (ASCVD).
| Characteristics | VHR group (n = 1511) | Non-VHR group (n = 2269) | ||||
|---|---|---|---|---|---|---|
| Moderate-intensity statin with ezetimibe (n = 757) | High-intensity statin monotherapy (n = 754) | P value | Moderate-intensity statin with ezetimibe (n = 1137) | High-intensity statin monotherapy (n = 1132) | P value | |
| Age, mean (SD), y | 63.6 (9.9) | 64.3 (10.3) | .19 | 63.5 (9.3) | 63.9 (9.2) | .37 |
| Sex, No. (%) | ||||||
| Female | 141 (18.6) | 154 (20.4) | .41 | 333 (29.3) | 326 (28.8) | .83 |
| Male | 616 (81.4) | 600 (79.6) | 804 (70.7) | 806 (71.2) | ||
| Body mass index, mean (SD)a | 25.0 (3.2) | 25.0 (3.0) | .82 | 25.1 (3.1) | 25.1 (3.1) | .58 |
| Prior myocardial infarction, No. (%) | 650 (85.9) | 631 (83.7) | .57 | 94 (8.2) | 114 (10.0) | .18 |
| Prior percutaneous coronary intervention, No. (%) | 648 (85.6) | 632 (83.8) | .37 | 610 (53.6) | 607 (53.6) | <.99 |
| Prior coronary bypass graft surgery, No. (%) | 58 (7.7) | 47 (6.3) | .35 | 74 (6.5) | 68 (5.9) | .65 |
| History of ischemic stroke, No. (%) | 93 (12.3) | 101 (13.4) | .57 | 8 (0.7) | 11 (1.0) | .64 |
| Chronic kidney disease, No. (%)b | 106 (14.0) | 106 (14.1) | <.99 | 87 (7.7) | 93 (8.2) | .68 |
| End-stage kidney disease receiving hemodialysis, No. (%) | 11 (1.5) | 12 (1.6) | .97 | 2 (0.2) | 4 (0.3) | .69 |
| Hypertension, No. (%) | 569 (75.2) | 574 (76.1) | .71 | 677 (59.5) | 700 (61.8) | .28 |
| Peripheral artery disease, No. (%) | 54 (7.1) | 56 (7.4) | .90 | 12 (1.1) | 13 (1.1) | .99 |
| Diabetes, No. (%) | 334 (44.1) | 327 (43.4) | .81 | 367 (32.3) | 370 (32.7) | .87 |
| Insulin treatment | 26 (3.4) | 34 (4.5) | .35 | 24 (2.1) | 36 (3.2) | .15 |
| Current smoker, No. (%) | 172 (22.7) | 164 (21.8) | .70 | 156 (13.7) | 146 (12.9) | .61 |
| Dyslipidemia treatment before randomization, No. (%) | ||||||
| Drug naive | 48 (6.3) | 53 (7.0) | .78 | 112 (9.9) | 103 (9.1) | .42 |
| Low-intensity statin | 4 (0.5) | 3 (0.4) | 2 (0.2) | 2 (0.2) | ||
| Moderate-intensity statin | 243 (32.3) | 262 (34.7) | 438 (38.5) | 423 (37.4) | ||
| Moderate-intensity statin with ezetimibe | 101 (13.3) | 89 (11.8) | 150 (13.2) | 159 (14.0) | ||
| High-intensity statin | 324 (42.8) | 316 (41.9) | 387 (34.0) | 413 (36.5) | ||
| High-intensity statin with ezetimibe | 37 (4.9) | 31 (4.1) | 48 (4.2) | 32 (2.8) | ||
| Heart failure, No. (%) | 46 (6.1) | 45 (6.0) | <.99 | 25 (2.2) | 24 (2.1) | <.99 |
| Baseline serum LDL-C, median (IQR), mg/dL | 78 (63-98) | 77 (62-97) | .60 | 82 (65-102) | 82 (65-102) | .61 |
| No. of patients with LDL-C <70 mg/dL, No. (%) | 272 (35.9) | 278 (36.9) | .75 | 371 (32.6) | 338 (29.9) | .17 |
Abbreviation: LDL-C, low-density lipoprotein cholesterol.
SI conversion factor: To convert LDL-C level to millimoles per liter, multiply by 0.0259.
a
Calculated as weight in kilograms divided by height in meters squared.
b
Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL per minute per 1.73 m2 of body surface area.